Muscularis mucosae invasion: Pronostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma;Atteinte de la Muscularis Mucosae dans les tumeurs urothéliales T1 de vessie: Facteur pronostique de progression après immunothérapie par BCG

Progres en Urologie

Volumn 22, Issue 5, 2012, Pages 284-290

  Nguyen Huu, Y ^a,b   Delorme, G ^a,b   Lillaz, J ^a,b   Bedgedjian, I ^c   Le Ray Ferrieres I ^d   Chabannes, E ^a   Bernardini, S ^a   Guichard, G ^a   Bittard, H ^a,b   Kleinclauss, F ^a,b,d  

^a HÔPITAL SAINT JACQUES   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d INSERM   (France)

Author keywords

Bacille Calmette Guerin; Intravesical immunotherapy; Muscularis Mucosae; Urinary bladder neoplasm

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CYSTECTOMY; DISEASE COURSE; FOLLOW UP; HUMAN; MORTALITY; MUCOSA; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

AGED; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MUCOUS MEMBRANE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84859835421     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2011.10.002     Document Type: Article

References (19)

1. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
2. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116:180-183.
3. Malmstrom P.U., Sylvester R.J., Crawford D.E., Friedrich M., Krege S., Rintala E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009, 56:247-256.
4. Han R.F., Pan J.G. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer?. A meta-analysis of randomized trials. Urology 2006, 67:1216-1223.
5. Pfister C., Roupret M., Wallerand H., Davin J.L., Quintens H., Guy L., et al. Recommendations onco-urology 2010: urothelial tumors. Prog Urol 2010, 20(Suppl. 4):S255-S274.
6. Hall M.C., Chang S.S., Dalbagni G., Pruthi R.S., Seigne J.D., Skinner E.C., et al. Guideline for the management of non muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178:2314-2330.
7. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bohle A., Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
8. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
9. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 2001, 166:1296-1299.
10. Bernardini S., Billerey C., Martin M., Adessi G.L., Wallerand H., Bittard H. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001, 165:42-46. [discussion 46].
11. Smits G., Schaafsma E., Kiemeney L., Caris C., Debruyne F., Witjes J.A. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 1998, 52:1009-1013. [discussion 1013-4].
12. Younes M., Sussman J., True L.D. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990, 66:543-548.
13. Faivre d'Arcier B., Celhay O., Safsaf A., Zairi A., Pfister C., Soulie M., et al. T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU). Prog Urol 2010, 20:440-449.
14. Margel D., Tal R., Golan S., Kedar D., Engelstein D., Baniel J. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 2007, 69:78-82.
15. Kondylis F.I., Demirci S., Ladaga L., Kolm P., Schellhammer P.F. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000, 163:1120-1123.
16. Orsola A., Trias I., Raventos C.X., Espanol I., Cecchini L., Bucar S., et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005, 48:231-238. [discussion 238].
17. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA. T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
18. Saint F., Irani J., Patard J.J., Salomon L., Hoznek A., Zammattio S., et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001, 57:883-888.
19. Fernandez-Gomez J., Solsona E., Unda M., Martinez-Pineiro L., Gonzalez M., Hernandez R., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008, 53:992-1001.